The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

• Główni autorzy: Chih-Jen Yang (Autor), Ming-Ju Tsai (Autor), Jen-Yu Hung (Autor), Mei-Hsuan Lee (Autor), Ying-Ming Tsai (Autor), Yu-Chen Tsai (Autor), Jui-Feng Hsu (Autor), Ta-Chih Liu (Autor), Ming-Shyan Huang (Autor), Inn-Wen Chong (Autor)
• Format: Książka
• Wydane: BMC, 2017-12-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Abstract Background Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been shown to have better efficacy in the treatment of non-small cell lung cancer harboring EGFR mutations. However, 40 mg dai...